76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Merck & Co Inc.
Open
SectorHealthcare
75.75 2.16
Overview
Share price change
24h
Min
74.34
Max
76.01
Income | 1.3B 5.1B |
|---|---|
Sales | -95M 16B |
P/E Sector Avg | 11.69 56.602 |
EPS | 2.22 |
Dividend yield | 4.26 |
Profit margin | 32.745 |
Employees | 73,000 |
EBITDA | 386M 7.3B |
Recommendations | Buy |
|---|---|
12 Months Forecast | +38.51% upside |
Dividend yield Sector Avg | 4.26% 2.45% |
|---|---|
Next Earnings | 29 Jul 2025 |
Next Dividend date | 7 Jul 2025 |
Next Ex Dividend date | 16 Jun 2025 |
Market Cap | -11B 202B |
|---|---|
Previous open | 73.59 |
Previous close | 75.75 |
News Sentiment
By Acuity
45%
55%
161 / 382 Healthcare
Technical Score
By Trading Central
Confidence
Bearish Evidence
Merck & Co Inc. Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Merck & Co Inc. Forecast
Price Target
By TipRanks
38.51% upside
12 Months Forecast
Average 101.76 USD 38.51%
High 138 USD
Low 82 USD
Based on 17 Wall Street analysts offering 12 month price targets forMerck & Co Inc. - Dist in the last 3 months.
Sentiment
By Acuity
161 / 382 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Merck & Co Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
